1h Free Analyst Time
Fate Therapeutics Inc (FATE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the publisher to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.Speak directly to the analyst to clarify any post sales queries you may have.
The profile contains critical company information including:
- Business description - A detailed description of the company’s operations and business divisions.
- Corporate strategy - Analyst’s summarization of the company’s business strategy.
- SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history - Progression of key events associated with the company.
- Major products and services - A list of major products, services and brands of the company.
- Key competitors - A list of key competitors to the company.
- Key employees - A list of the key executives of the company.
- Executive biographies - A brief summary of the executives’ employment history.
- Key operational heads - A list of personnel heading key departments/functions.
- Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights
Fate Therapeutics Inc (Fate Therapeutics) is a biopharmaceutical company that develops programmed cellular therapies for cancer and immune disorders. The company’s pipeline includes various off-the-shelf, iPSC-derived cellular immunotherapies for the treatment of several hematological malignancies and advanced solid tumors. Its pipeline also includes a donor-derived cell product candidate for the treatment of hematological malignancies. Fate uses its proprietary human-induced pluripotent stem cell (iPSC) platform for product development. The company also has research collaborations with companies, academic centers and medical centers for the advancement of products and technologies. Fate Therapeutics is headquartered in San Diego, California, the US.Fate Therapeutics Inc Key Recent Developments
- Feb 28, 2023: Fate Therapeutics Reports Fourth Quarter and Full Year 2022
- Jan 05, 2023: Fate Therapeutics announces termination of collaboration agreement with Janssen, pipeline prioritization, next-generation programs, and key 2023 initiatives
- Dec 13, 2022: Fate Therapeutics features multiple novel approaches to eliminate conditioning chemotherapy for off-the-shelf, iPSC-derived cell therapies at 2022 ASH Annual Meeting
- Nov 03, 2022: Fate Therapeutics to present clinical and preclinical data for iPSC product platform at the 2022 ASH Annual Meeting
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Table of Contents
Section 1 - About the Company
Section 2 - Company Analysis
Section 3 - Company Financial Ratios
Section 4 - Company’s Lifesciences Financial Deals and Alliances
Section 5 - Company’s Recent Developments
Section 6 - Appendix
List of Tables
List of Figures
Companies Mentioned
A selection of companies mentioned in this report includes:
- Adaptimmune Therapeutics Plc
- Nkarta Inc
- Johnson & Johnson
- ImmunityBio Inc
- Gilead Sciences Inc
- CRISPR Therapeutics AG
- Legend Biotech Corp
- Iovance Biotherapeutics Inc
- Atara Biotherapeutics Inc
- Allogene Therapeutics Inc
- Sanofi
- Celularity Inc
- Caribou Biosciences Inc
- Bristol-Myers Squibb Co
- Takeda Pharmaceutical Co Ltd
- Precision Biosciences Inc
- Novartis AG
- Intellia Therapeutics Inc
- Cellectis SA
- Sana Biotechnology Inc
- Precision Biosciences Inc
- Intellia Therapeutics Inc
- Nkarta Inc
- Gilead Sciences Inc
- CRISPR Therapeutics AG
- Sanofi
- Celularity Inc
- Caribou Biosciences Inc
- Bristol-Myers Squibb Co
- Atara Biotherapeutics Inc
- Allogene Therapeutics Inc
- bluebird bio Inc
- Takeda Pharmaceutical Co Ltd
- Novartis AG
- Sorrento Therapeutics Inc
- Legend Biotech Corp
- Iovance Biotherapeutics Inc
- Adaptimmune Therapeutics Plc
- Johnson & Johnson
- ImmunityBio Inc
- Bellicum Pharmaceuticals Inc
- Cellectis SA